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Abstract
Background: The importance of acquiring comprehensive epidemiological and clinical data on
hereditary angioedema has increasingly caught the attention of physicians and scientists around the
world. The development of networks and creation of comprehensive policies to improve care of
people suffering from rare diseases, such as hereditary angioedema, is a stated top priority of the
European Union.
Hereditary angioedema is a rare disease, that it may be life-threatening. Although the exact
prevalence is unknown, current estimates suggest that it is 1/10,000–1/150,000 individuals. The low
prevalence requires combined efforts to gain accurate epidemiological data on the disease and so
give us tools to reduce morbidity and mortality, and improve quality of life of sufferers.
Methods: Sweha-Reg is a population-based registry of hereditary angioedema in Sweden with the
objectives of providing epidemiological data, and so creates a framework for the study of this
disease. The registry contains individual-based data on diagnoses, treatments and outcomes.
Conclusion: The present manuscript seeks to raise awareness of the existence of Sweha-Reg to
stimulate the international collaboration of registries. A synthesis of data from similar registries
across several countries is required to approach an inclusive course understanding of HAE.
Background
Hereditary angioedema (HAE) is a rare and potentially
life-threatening condition that clinically manifests itself as
acute attacks of facial, laryngeal, genital and peripheral
swelling and/or recurrent abdominal pain, with a signifi-
cant effect on the quality of life of sufferers [1]. The condi-
tion can have profound physical and psychological
effects, which can prevent a normal social activity.
The disease results from deficient production (HAE-I) or
function (HAE-II) of C1 esterase inhibitor (C1-INH), and
is caused by mutation of the C1NH gene on chromosome
11 [2]. To date, approximately 190 different C1NH muta-
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tions are known [3]. The disorder, which has an dominant
hereditability, has traditionally been described in 2 types:
HAE-I and HAE-II [4,5]. However, recently it has been
proposed a third type (HAE-III), with normal C1-INH
activity and unknown pathomechanism [6,7]. Although
recent reports proposed increased activity of coagulation
factor XII (Hageman factor) as a possible cause of HAE
type III [8,9].
Despite the substantial immunogenetic knowledge that
has been amassed, different aspects of HAE are only par-
tially understood. In Sweden, basic epidemiological
parameters such as prevalence and incidence are lacking,
and patient materials investigated are very small and often
only include selected subgroups. Moreover, there is no
national consensus on what constitutes state-of-the-art
evidence-based treatment and consequently patients are
treated differently at various centers. Also, lack of compre-
hensive epidemiological data has further decreased the
value of case reports that appear to link purported eliciting
factors to the occurrence of attacks. Accordingly, a team of
physicians and scientists in Sweden have initiated a
national population-based patient register (Sweha-Reg)
with the objective of gaining a better understanding of
HAE, including its epidemiology, clinic and management.
The present manuscript presents the Sweha-Reg and is
also an effort to stimulate the international collaboration
of registries. Cross linking of similar registries across sev-
eral countries is required to approach an inclusive presen-
tation and course understanding of HAE.
Methods
Historically, Swedish health care has generally been pop-
ulation-based, since it is mainly funded by taxes and pri-
vate health-care providers have been scarce.
Since January 1, 1947, all inhabitants of Sweden have
been assigned a 10-digit national registration number,
which is a unique personal identifier. Since it is used in
most registries it provides an opportunity to unambigu-
ously link information from different sources.
Sweha-Reg
Sweha-Reg is a population-based census of HAE in Swe-
den, established to achieve a baseline epidemiological
description, and to provide a framework to study quality
of life, and to further characterize the disease. The registry
attempts to capture data on all individuals with diagnosed
or suspected HAE type I and II in Sweden by using multi-
ple recruitment channels, and to record enough clinical
information, including biochemical diagnostic markers to
assure a case definition with high sensitivity and specifi-
city, accurately excluding those with non-hereditary
angioedema. Sweha-Reg is a nation-wide registry that
serves the entirety of Sweden, which is estimated to have
a population of 9.1 million people.
Cases are prospectively followed over time for disease
course, efficacy, safety and outcome of different treat-
ments, for co-morbidities and quality of life. Furthermore,
we have used the Swedish Population Registry to identify
a set of control subjects matched to the first 100 adult
cases (> 18 yrs old) enrolled during early 2007. The con-
trols are selected from the Stockholm County as a strati-
fied random sample, taking age and sex into
consideration. Three control subjects are selected per
adult case.
Additionally, biological specimens, including serum,
plasma and whole-blood are collected for studying the
biochemical, immunological and genetical background of
the patients. Data obtained from this biobank (Sweha-
Bank) can be useful for describing common polymor-
phisms in Sweden, establishing a basis for biobank-based
post-genome studies, integrating phenotype and genotype
data. The stored biological specimens are useful also for
other pertinent research.
Case definition and recruitment
In brief, the cases comprise individuals at any age with a
diagnosis and/or treatment of HAE type I and II, and who
live in Sweden. Diagnosis and classification of HAE is
made using established criteria and terminology [10].
Only subjects with a convincing clinically and laboratory
diagnosis of HAE are included. In situations in which the
diagnosis is uncertain, additional previous medical
records are requested to determine an accurate diagnosis.
Patients are recruited nationwide. In order to enroll as
many cases as possible, multiple recruitment sources are
used, such as physicians and clinics specialized in HAE,
hospital discharge databases and periodic correspondence
with all medical directors of dermatologic, pediatric, aller-
gologic and internal medicine clinics at Swedish hospi-
tals, as well as the immunologic HAE-laboratories in Lund
and Uppsala. Additional cases are recruited through
advertisements, campaigns on the website and magazine
of the Primary Immunodeficiency Organization (PIO) in
Sweden.
Once a potential case is identified, informed consent to
approach the patient to join the registry and to release
medical information is obtained via the treating physi-
cian. This process is most straightforward for patients
treated by the registry investigators. To enlist cases han-
dled by other physicians, the registry sends the survey
information to the treating physician to pass on to
patients. Thus, all patients are contacted through their
treating physicians. Unlike some other population-basedBMC Dermatology 2007, 7:6 http://www.biomedcentral.com/1471-5945/7/6
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registries, such as The Swedish Cancer Registry, there is no
requirement on the part of hospitals or treating physicians
to report HAE cases. Moreover, the Sweha-Reg requires
consent for patient participation. These issues add to the
challenge of completeness of case-participation. In order
to optimize participation, there is no absolute require-
ment for patients to provide blood samples. In addition
self referral is possible through contacting the survey's tel-
ephone hotline or e-mail service. By means of these serv-
ices patients and physicians are also able to receive advice
and counsel with regard to any question related to the
Sweha-project and/or HAE in general.
Moreover, close collaboration within the Sweha study
group, involving HAE-leading physicians in Sweden,
plays a crucial role in the recruitment process. This study
group also disseminates information on Sweha-Reg and
fosters a constructive collaboration between investigators
and treating physicians.
Participation
Participation involves answering a mailed questionnaire,
followed by attending a standardized telephone interview
by a physician, and for those who live near one of the sur-
vey's qualified laboratory centers, to provide blood sam-
ples for laboratory analyses and for storage in Sweha-
Bank.
Written informed consent is obtained from the study par-
ticipants or their parents (for individuals aged < 18 yrs)
prior to the telephone interview. Parental interviews are
conducted for patients with an age less than 12 yrs of age.
Control individuals answer an identical questionnaire as
cases, but do not attend the telephone interview.
Blood samples, a total amount of approximately 40 ml
(less in young children), are collected at one of the quali-
fied laboratories, assuring the appropriate systems for bio-
logical specimen collection, processing and storage. The
labs are located in 4 different areas in Sweden (Lund,
Jönköping, Göteborg and Stockholm). The Sweha-survey,
including the registry and biobank, is approved by the
ethics committee of the Karolinska Institutet, Sweden. The
survey is performed according to the Declaration of Hel-
sinki Principles.
Questionnaire
Registry participants are mailed a questionnaire with up
to 3 reminder follow-up letters if it is not returned. For
patient's convenience the questionnaire is in paper for-
mat. However Sweha-Reg, consisting of data from the
questionnaire and the telephone interview, exists in dig-
ital format which could easily be adapted as a web-based
register, if such a design is found beneficial. Once the
questionnaire is returned it is transferred to the digital for-
mat.
Information on demographic data, social, educational,
economical, and health status, quality of life, family his-
tory of HAE, co-morbidities, potentially predisposing trig-
ger factors surrounding onset and new attacks, previous
and ongoing medication and attacks characterization and
severity of symptoms are obtained by answering 38 ques-
tions.
Telephone interview
The telephone interview is structured to capture the natu-
ral course of HAE and the efficacy, safety and outcome of
different treatments in patients and the extent of usage of
health and social services. Furthermore, information
about potential precipitating factors and co-morbidities,
provided through the mailed questionnaire, is verified
and missing or unclear data are completed. Additional
information includes family history of HAE. Besides, the
telephone interview provides patients with the opportu-
nity to raise questions related to their disease and its treat-
ment.
Confidentiality of Patient Records
Due to patient confidentiality requirements, all subjects
receive a unique study-identification code, which ano-
nymizes the records. Only the registry's main investigators
(CFW and LM) know the code and are able to link an indi-
vidual report to an individual patient. Access to data will
initially be restricted to the Sweha study group physicians
participating in the concerted action but will eventually be
open, on request, to any HAE-treating physician. Also, cli-
nicians contributing to the register will have access to the
data of their own patients, and will obtain (by request)
feedback such as individual or group reports.
The survey board, consisting of the authors of the present
manuscript, manages the anonymized database and may
access aggregated reports but not individual data sets. No
single member of the board can use or publish the data
without the consent of the board and the contributors as
a whole.
Cross-linking of registries
One of the Sweha-Reg's objectives is to be able to share
and compare data with other similar HAE-registries in
other nations. In this context, some of the questions are
designed to be compatible with data in the European HAE
registry [11]. Moreover, by using the unique Swedish per-
sonal identification number, we are able to crosslink
Sweha-Reg to other population-based registries, such as
The Swedish Cancer Registry, Hospital Discharge Patient
Registry, National database for Acute Myocardial Infarc-
tion and Cause-of-death Register.BMC Dermatology 2007, 7:6 http://www.biomedcentral.com/1471-5945/7/6
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Conclusion
HAE is a rare autosomal dominant disease that like other
rare disorders is seldom seen by the individual physician,
unless he/she is highly specialized. The potential lethality
of the condition emphasizes the importance of building
professional networks to develop uniform and accurate
management guidelines and to reveal different outcomes
including clinical, psychological and economical varia-
bles associated with the disease and its management.
Establishing population-based registry of HAE is an essen-
tial first step in addressing these most important issues.
The ultimate objective of Sweha-Reg is to improve the
welfare and health of patients with HAE. However, the
chain from collecting the data in a registry to improved
health and/or quality of life in individuals with HAE is
long, complex and difficult to achieve. Therefore a more
realistic intermediate objective of Sweha-Reg is to offer a
fundamental source of information which can be useful
for improving disease management and patient care, tar-
geting preventive measurements to lessen co-morbidities
and thereby improving quality of life in sufferers. Such an
epidemiological registry is a basic prerequisite for obtain-
ing a comprehensive and an accurate description of a rare
disease such as HAE.
The information gained from Sweha-Reg can serve as a
resource for quality control of treatment and patient care
by clinicians and other health care providers, scientists,
public health officials and researchers, by providing them
a finger on the pulse of HAE in Sweden. The health care
services depend on such quality controls to review their
activities meaningfully.
The design of the registry permits analysis of different
patient subpopulations, including pediatric patients or
patients whose angioedema worsens during specific con-
ditions such as pregnancy or hormone administration.
Moreover, Sweha-Reg not only allows scientists to con-
duct case-control-studies but also prospective cohort stud-
ies, and to cross-link data to other population-based
registries with the ability to follow up subjects to obtain
information on other outcomes. Hopefully new useful
patterns will emerge out of such epidemiological data.
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